TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04882553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of esophageal pressure
Description: Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Registration of respiratory mechanics
Description: Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
Study: NCT06436352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsulotomy and fixation
Description: Firstly, Guide wire insertion passing anterior to the GT and the neck is done. then passing a pointed Schanze 5 or 6 ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.~Then we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation only
Description: we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex.
Study: NCT06247735

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily
Study: NCT05124912

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: Post-op hypofractionated therapy or no radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Steroid Therapy
Description: Best medical management with steroid therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Interstitial Thermal Therapy
Description: Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Interstitial Thermal Therapy
Description: Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
Study: NCT04516603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR
Description: Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active component
Study: NCT06315309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Combined with Tacrolimus and Mini Methotrexate
Description: On Day -7, subjects will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). Subjects will receive a steroid injection 3 hours before every ATG infusion. On day -6, subjects will receive a small dose of ATG as an IV infusion. ATG will be repeated on days -5,-4 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -6 to -2 as daily IV infusions. Busulfan, a routine transplant chemotherapy will be given on days -5 to -2 as IV infusion. Subjects with lymphoblastic leukemia will receive an alternative regimen of cyclophosphamide, a routine chemotherapy on days -6 and -5, followed by total body radiation on days -3 to -1. Tacrolimus (standard immune suppression agent) starts on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate a standard immune suppression medication which is given IV on day +1,+3,+6, and +11 post-transplant. Blood draws on days -4,-1,+3,+7,+14 to measure ATG levels.
Study: NCT06184997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTAKE OF ISOTONIC DRINK
Description: Intake of natural isotonic drink based on 20% Atlantic sea water, mixed with lemon and stevia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Intake of natural mineral water
Study: NCT05144347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL114
Description: Tablets of XL114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL114
Description: Tablets of XL114
Study: NCT06138171

Intervention type: OTHER
Intervention: Psychological self-reported measures assesment (questionnaire)
Description: The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
Study: NCT05624112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab solution in a pre-filled syringe for Subcutaneous injection
Study: NCT06138171

Intervention type: OTHER
Intervention: Psychological self-reported measures assesment (questionnaire)
Description: The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).

Intervention type: OTHER
Intervention: Psychological self-reported measures assesment (questionnaire)
Description: The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).

Intervention type: OTHER
Intervention: Psychological self-reported measures assesment (questionnaire)
Description: The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
Study: NCT06444360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: The IMPACT intervention consists of 10 sessions: 2 sessions focused on HIV acquisition/transmission risk reduction (RR), 1 session focused on orienting and rationale to behavioral activation (BA), 6 sessions integrating BA and HIV RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSOC
Description: The eSOC group consists of 2 sessions focused on HIV acquisition/transmission risk reduction (RR).
Study: NCT04683913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot rotation modification
Description: The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot rotation modification
Description: The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting Period - Delayed Group
Description: Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
Study: NCT05838742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be administered.
Study: NCT06350565

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
Study: NCT05838742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05086393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Patients will be randomized to receive Duloxetine or a placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will be randomized to receive Duloxetine or a placebo.
Study: NCT05261711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1
Description: This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
Study: NCT06400615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD109
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD109
Description: Oral administration at bedtime
Study: NCT05865145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Bicycle Ergometer
Description: Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Bicycle Ergometer
Description: Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
Study: NCT05395546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dCBT-I
Description: 1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~3. Scale assessment needs to be completed at the end of treatment~4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation
Study: NCT06331611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF monitoring
Description: Reversal with Sugammadex will be based on TOF monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOF monitoring
Description: Reversal with Sugammadex will be based on TOF monitoring
Study: NCT06168149

Intervention type: DIAGNOSTIC_TEST
Intervention: fetal lung elastography measurement
Description: Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file.

Intervention type: DIAGNOSTIC_TEST
Intervention: fetal lung elastography measurement
Description: Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file.
Study: NCT04431297

Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness Rounds
Description: Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
Study: NCT06497959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: Placental contrast ultrasound using SonoVue by maternal intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: Placental contrast ultrasound using SonoVue by maternal intravenous injection
Study: NCT06051175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bitter taste perception
Description: Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salty taste perception
Description: Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet taste perception
Description: Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.
Study: NCT05023577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd
Study: NCT05054322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone propionate added to usual care, total dose 1000 mcg per day for 14 days
Study: NCT05720975

Intervention type: DEVICE
Intervention: iNstroke
Description: Patients to undergo thromboaspiration with iNstroke.
Study: NCT04870723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth for Covid-19 prevention and support
Description: 3-session online peer-counseling intervention based on motivational interviewing and psychoeducation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: eHealth for Covid-19 prevention and support
Description: 3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
Study: NCT06371144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Analgestic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Analgestic
Study: NCT05566964

Intervention type: DEVICE
Intervention: ME&MGopen smartphone application
Description: Smartphone application includes digital tests and e-questionnaires
Study: NCT05260164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFEM+RF
Description: Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
Study: NCT05343052

Intervention type: OTHER
Intervention: Patient Reported Outcomes Surveys
Description: * Oslo Sports Trauma Research Center Hamstring Injury Screening Questionnaire (HaOS) at baseline~* Functional Assessment Scale for Acute Hamstring Injuries (FASH) within 7 days of injury and within 7 days of return to sport (RTS)

Intervention type: OTHER
Intervention: Clinical Assessments
Description: * Injury History at baseline, within 7 days of injury, within 7 days of RTS~* Pain and Function Assessments within 7 days of injury, within 7 days of RTS

Intervention type: OTHER
Intervention: Biomechanical and Neuromuscular Assessments
Description: * Eccentric Strength measure at baseline and within 7 days of RTS~* Sprinting Biomechanics at baseline and within 7 days of RTS

Intervention type: DEVICE
Intervention: Conventional MRI
Description: at baseline, within 7 days of injury, and within 7 days of RTS
Study: NCT05776758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin based neoadjuvant chemotherapy
Description: cisplatin based neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy alone
Description: RC alone
Study: NCT06051175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acid taste perception
Description: Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umami taste perception
Description: Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.
Study: NCT05045534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment
Study: NCT05776758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical cystectomy alone
Description: RC alone